Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
NEW YORK, March 20, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of investors who purchased Argos Therapeutics, Inc. ("Argos") (NASDAQ:ARGS) securities between February 7, 2014 and February 21, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/argos-therapeutics-inc. There is no cost or obligation to you.
According to the complaint, Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).
On February 22, 2017, despite positive statements made by the Company, Argos then announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.
If you suffered a loss in Argos you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/argos-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
